Argen X SE ADR (ARGX): Next-Year EPS Estimate 32.79%
As of 2026-10-10, Argen X SE ADR (ARGX) has a next-year EPS growth estimate of 32.79%. Featured in 3 EPS revision reports, most recently on 2026-08-20.
On 2026-10-09, analyst consensus for ARGX's next-year EPS growth shifted from 32.98% to 32.79% — a negative change of 0.19 percentage points. The revised estimate has been sustained across 2 subsequent trading sessions. Current-year growth is projected at 50.04%.
What's Driving This
The primary structural driver is the 2026-09-08 analyst upgrade to ARGX’s next-year EPS growth estimate, now 33.76% versus 33.66%. Recent headlines attribute the stock’s rise to positive Phase 3 ALKIVIA results for Vyvgart in autoimmune myositis, a catalyst that may support future earnings expectations even though it is not an EPS revision itself. Repeated coverage and record-high share movement suggest momentum has continued beyond the initial estimate change.
Generated 2026-09-11 from news as of 2026-09-11
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 32.79%
- EPS growth this year
- 50.04%
- EPS next quarter (est)
- $7.90
- Last price
- $825.03
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-10-10 | 32.79% | 50.04% | $7.90 | $825.03 |
| 2026-10-09 | 32.79% | 50.04% | $7.90 | $825.03 |
| 2026-10-08 | 32.98% | 50.02% | $7.95 | $818.63 |
| 2026-10-07 | 33.24% | 47.48% | $7.71 | $928.44 |
| 2026-10-06 | 33.24% | 47.48% | $7.71 | $930.52 |
| 2026-10-05 | 33.24% | 47.48% | $7.71 | $912.87 |
| 2026-10-04 | 33.24% | 47.48% | $7.71 | $919.21 |
| 2026-10-03 | 33.24% | 47.48% | $7.71 | $919.21 |
| 2026-10-02 | 33.24% | 47.48% | $7.71 | $919.21 |
| 2026-10-01 | 33.24% | 47.48% | $7.67 | $936.00 |
| 2026-09-30 | 33.43% | 47.27% | $7.67 | $958.91 |
| 2026-09-29 | 33.43% | 47.27% | $7.67 | $970.66 |
| 2026-09-28 | 33.43% | 47.27% | $7.67 | $972.25 |
| 2026-09-27 | 33.43% | 47.27% | $7.67 | $959.49 |
| 2026-09-25 | 33.43% | 47.27% | $7.67 | $959.49 |
| 2026-09-24 | 33.48% | 47.15% | $7.64 | $962.22 |
| 2026-09-23 | 33.48% | 47.15% | $7.64 | $945.82 |
| 2026-09-22 | 33.48% | 47.15% | $7.64 | $963.79 |
| 2026-09-21 | 33.48% | 47.15% | $7.64 | $988.20 |
| 2026-09-20 | 33.56% | 47.23% | $7.61 | $990.32 |
| 2026-09-18 | 33.56% | 47.23% | $7.61 | $990.32 |
| 2026-09-17 | 33.54% | 47.23% | $7.61 | $995.77 |
| 2026-09-16 | 33.58% | 47.23% | $7.61 | $984.69 |
| 2026-09-15 | 33.53% | 47.55% | $7.61 | $979.76 |
| 2026-09-14 | 33.38% | 47.64% | $7.61 | $990.54 |
| 2026-09-13 | 33.76% | 47.58% | $7.61 | $984.39 |
| 2026-09-11 | 33.76% | 47.58% | $7.61 | $984.39 |
| 2026-09-10 | 33.76% | 47.58% | $7.61 | $984.04 |
| 2026-09-09 | 33.76% | 47.58% | $7.61 | $1002.31 |
| 2026-09-08 | 33.76% | 47.58% | $7.61 | $1007.07 |
Reports Featuring ARGX
Recent News
- argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive DirectorsGlobeNewswire
- Intuit downgraded, SolarEdge upgraded: Wall Street's top analyst callsThe Fly
- Argenx Stock Heads for Record After Blockbuster Drug Delivers Another WinBarrons.com
- Argenx Stock Heads for Record After Blockbuster Drug Delivers Another WinBarrons.com
- Argenxs stock rises on Phase III autoimmune myositis victoryClinical Trials Arena
- Argenxs stock rises on Phase III autoimmune myositis victoryClinical Trials Arena
- argenx Phase 3 ALKIVIA Trial Meets Primary Endpoint in Autoimmune MyositisInvestorsHub
- argenx Phase 3 ALKIVIA Trial Meets Primary Endpoint in Autoimmune MyositisInvestorsHub
- Argenx's Vyvgart Scored Another Win - Why Shares Bolted HigherInvestor's Business Daily
- Argenx's Vyvgart Scored Another Win - Why Shares Bolted HigherInvestor's Business Daily
Screen Performance
Aggregate stats across all 2077 tickers our top-EPS-revision screen has flagged over the past 192 days.
- Median return since detection
- -0.9%
- % of tickers in the green
- 47%
- Median return on winners
- +23.2%
- Large revisions captured
- 1848
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Argen X SE ADR's next-year EPS growth estimate?▾
As of 2026-10-10, Argen X SE ADR (ARGX) has a next-year EPS growth estimate of 32.79%, based on analyst consensus.
When was the latest EPS estimate revision for ARGX?▾
The most recent revision occurred on 2026-10-09, when analysts adjusted the next-year EPS growth estimate from 32.98% to 32.79%.
What sector and industry does Argen X SE ADR belong to?▾
Argen X SE ADR operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. ARGX appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Argen X SE ADR (ARGX) appears here because it was detected by our daily top-EPS-revision-performer screen.